Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-01-23
2008-08-05
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S277000, C514S279000, C514S281000, C530S329000, C546S139000
Reexamination Certificate
active
07407939
ABSTRACT:
The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.
REFERENCES:
patent: 5475110 (1995-12-01), Hudkins et al.
patent: 5516771 (1996-05-01), Dionne et al.
patent: 5591855 (1997-01-01), Hudkins et al.
patent: 5594090 (1997-01-01), Bender
patent: 5650407 (1997-07-01), Mallamo et al.
patent: 5654427 (1997-08-01), Dionne et al.
patent: 5985877 (1999-11-01), Dionne et al.
patent: 6034097 (2000-03-01), DiMaio et al.
patent: 6174993 (2001-01-01), Ben-Sasson
patent: 6528486 (2003-03-01), Larsen et al.
patent: 6559139 (2003-05-01), Johnson et al.
patent: 6667337 (2003-12-01), Wilson
patent: 6943148 (2005-09-01), Ekwuribe et al.
patent: 6949565 (2005-09-01), Livnah et al.
patent: 7034026 (2006-04-01), Barnett et al.
patent: 7037891 (2006-05-01), Ben-Sasson
patent: 2002/0065221 (2002-05-01), Cohen et al.
patent: 2003/0224383 (2003-12-01), West et al.
patent: 2005/0026840 (2005-02-01), Livnah et al.
patent: 2005/0053594 (2005-03-01), Russel
patent: 2005/0106152 (2005-05-01), Hikichi et al.
patent: 2006/0142178 (2006-06-01), Sutton
patent: 2007/0078092 (2007-04-01), Livnah et al.
patent: WO 96/11933 (1996-04-01), None
patent: WO 97/22360 (1997-06-01), None
patent: WO 01/70770 (2001-09-01), None
patent: WO 01/91754 (2001-12-01), None
patent: WO 03/010281 (2003-02-01), None
Dario R. Alessi et al., “Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase,” FEBS Letters 399, pp. 333-338 (1996).
Yi Fang et al., “Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-α/cycloheximide-induced apoptosis by regulating protein kinase B levels,”Eur. J. Biochem, vol. 268, pp. 4513-4519 (2001).
Hiroyoshi Hidaka et al, “Isoquinolinesulfonamides, Novel and Potent Inhibitors of Cyclic Nucleotide Dependent Protein Kinase and Protein Kinase C,”Biochemistry, vol. 23, pp. 5036-5041 (1984).
Chandra C. Kumar et al., “Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling,”Biochimica et Biophysica Acta, vol. 1526, pp. 257-268 (2001).
Ai-xue Liu et al., “AKT2, a Member of the Protein Kinase B Family, Is Activated by Growth Factors, v-Ha-ras, and v-srcthrough Phosphatidylinositol 3-Kinase in Hunan Ovarian Epithelial Cancer Cells,”Cancer Research, vol. 58, pp. 2973-2977 (1998).
Mart Loog et al., “Adenosine-5′-Carboxylic Acid Peptidyl Derivatives as Inhibitors of Protein Kinases,”Bioorganic&Medicinal Chemistry Letters, vol. 9, pp. 1447-1452 (1999).
Robert Martell et al., “Effects of Protein Kinase Inhibitors 1(5-Isoquinolinesulfonyl)-2-Methylpiperazine Dihydrochloride (H-7) and N-[2-Guanidinoethyl]-5-Isoquinolinesulfonamide Hydrochloride (HA1004) on Calcitriol-Induced Differentiation of HL-60 Cells,”Biochemical Pharmacology, vol. 37, pp. 635-640 (1988).
Karleen Nicholson et al., “The protein kinase B/Akt signalling pathway in human malignancy,”Cellular Signalling, vol. 14, pp. 381-395 (2002).
Masakatsu Nishikawa et al., “1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine(H-7), A Potent Inhibitor of Protein Kinases, Inhibits the Differentiation of HL-60 Cells Induced by horbol Diester”, Life Sciences, vol. 39, pp. 1101-1107 (1986).
Toshiyuki Obata et al., “Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB*,”The Journal of Biological Chemistry, vol. 275, No. 46, pp. 36108-36115 (2000).
Keykavous Parang et al., “Mechanism-based design of a protein kinase inhibitor,”Nature Structure Biology, vol. 8, No. 1, pp. 37-41 (2001).
G. Perez-Tenorio et al., “Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients,”British Journal of Cancer, vol. 86, pp. 540-545 (2002).
Ricouart et al., “Design of Potent Protein Kinase Inhibitors Using the Bisubstrate Approach,”J. Med. Chem., vol. 34, pp. 73-78 (1991).
Baljinder Salh et al., “Dysregulation of Phosphatidylinositol 3-Kinase and Downstream Effectors in Human Breast Cancer,”Int. J. Cancer, vol. 98, pp. 148-154 (2002).
Martin Schlitzer et al., “Design, Synthesis and Early Structure—Activity Relationship of Farnesyltransferase Inhibitors Which Mimic Both the Peptidic and the Prenylic Substrate,”Biorganic&Medicinal Chemistry, vol. 8, pp. 1991-2006 (2000).
Shuho Semba et al., “The in Vitro and in Vivo Effects of 2-(4-Morpholinyl)-8-phenylchromone (LY294002), a Specific Inhibitor of Phosphatidylinositol 3′-Kinase, in Human Colon Cancer Cells,”Clinical Cancer Research, vol. 8, pp. 1957-1963 (2002).
V. Waldmann et al., “Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma”Melanoma Research, vol. 12, pp. 45-50 (2002).
Michael J. Zinda et al., “AKT-1, 2, and -3 are Expressed in Both Normal and Tumor Tissues of the Lung, Breast, Prostate, and Colon,”Clinical Cancer Research, vol. 7, pp. 2475-2479 (2001).
Jian-Yuan Zhou et al., “Novel Vitamin D Analogs That Modulate Leukemic Cell Growth and Differentiation With Little Effect on Either Intestinal Calcium Absorption or Bone Calcium Mobilization” Blood, vol. 74 No. 1 pp. 82-93, (1989).
Gilbert Chu, “Cellular Responses to Cisplatin—The Roles of DNA-Binding Proteins and DNA Repair” The Journal of Biological Chemistry, vol. 269, No. 2, pp. 787-790, (1994).
Kay W. Colston et al., “Possible Role for Vitamin D in Controlling Breast Cancer Cell Proliferation” The Lancet, pp. 188-191 (1989).
David A. Fuchs et al., “Cytologic Evidence That Taxol, an Antineoplastic Agent From Taxus brevifolia, Acts as a Mitotic Spindle Poison” Cancer Treatment Reports vol. 62, No. 8, pp. 1219-1222 (1978).
Hiroyoshi Hidaka, et al. “Isoquinolinesulfonamides, Novel and Potent Inhibitors of Cyclic Nucleotide Dependent Protein Kinase and Protein Kinase C”, Biochemistry, vol. 23, pp. 5036-5041 (1984).
Michelle M. Hill, et al. “Inhibition Of Protein Kinase B/Akt: Implications For Cancer Therapy” Pharmacology & Therapeutics, vol. 93 pp. 243-251 (2002).
Jerry A. Howle et al. “CIS-Dichlorodiammineplatinum (II) Persistent And Selective Inhibition Of Deoxyribonucleic Acid SynthesisIn Vivo” Biochemical Pharmacology, vol. 19, pp. 2757-2762 (1970).
Maria Lindgren et al. “Cell-Penetrating Peptides” TiPS, vol. 21, pp. 99-103 (2000).
Ai-xue Liu, et al. “AKT2, A Member Of The Protein Kinase B Family, Is Activated By Growth Factors, v. Ha-ras, And v-src Through Phosphatidylinositol 3-Kinase In Human Ovarian Epithelial Cancel Cells” Cancer Research, vol. 58, pp. 2973-2977 (1998).
Narima M. lopes, et al. “Cell Kill Kinetics And Cell Cycle Effects Of Taxol On Human And Hamster Ovarian Cell Lines”, Cancer Chemotherapy Pharmacol., vol. 32, pp. 235-242 (1993).
James J. Manfredi, et al. “Taxol: An Antimitotic Agent With A New Mechanism Of Action”, Pharmac. Ther., vol. 25, pp. 83-125 (1984).
Mariann C. McElwain, et
Cohen Ilana
Litman Pninit
Livnah Nurit
Ohne Onsat
Perlmutter Boris
Cooper & Dunham LLP
CureGenics Ltd.
Gupta Anish
White John P.
LandOfFree
Protein kinase inhibitors comprising ATP mimetics conjugated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase inhibitors comprising ATP mimetics conjugated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase inhibitors comprising ATP mimetics conjugated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4008464